Integra LifeSciences Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides 2019 Financial Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Integra LifeSciences (IART) Tops Q4 EPS by 3c, Revenues Beat; Offers FY19 EPS Mid-Point Guidance Above Consensus, FY19 Revenue Views Below Estimates
February 21, 2019 6:13 AM ESTIntegra LifeSciences (NASDAQ: IART) reported Q4 EPS of $0.65, $0.03 better than the analyst estimate of $0.62. Revenue for the quarter came in at $383.3 million versus the consensus estimate of $381.73 million.
Fourth Quarter 2018 HighlightsReported revenue was $383.3 million, an increase of 4.0% over the prior year, while organic sales were higher by 4.4% over the prior year;GAAP earnings per diluted share amounted to $0.29, compared to $0.56 in the prior year; fourth quarter adjusted earnings per diluted share amounted to $0.65, compared to $0.64 in... More